Form 10-Q BRISTOL MYERS SQUIBB CO For: Mar 31
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Bristol-Myers (BMY) Bullish Stance Reiterated at BMO Capital Post Q1 and Ahead of ASCO Inflection for Opdivo
April 29, 2015 9:01 AM EDTBMO Capital analyst Alex Arfaei reiterated an Outperform rating and $75 on Bristol-Myers Squibb Co. (NYSE: BMY) following Q1 results and as ASCO should be an inflection point for Opdivo.
commented, "On the surface, 1Q looked solid: 6% topline beat, EPS $0.71 vs. $0.51. However, the Abilify beat is short-lived, and focus remains on the IO franchise. As we expected Yervoy sales were 6% below consensus, probably reflecting increased competition, and Opdivo sales... More
